resiquimod has been researched along with Cancer of Skin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Geary, SM; Naguib, YW; Salem, AK; Tambunlertchai, S | 1 |
| Goto, M; Kamiya, N; Kozaka, S; Sakuragi, M; Tahara, Y; Wakabayashi, R | 1 |
| Allred, JB; Block, MS; Markovic, SN; Nevala, WK; Pang, YP; Strand, C | 1 |
| Benoit, B; Buchanan, MA; Clark, RA; Elenitsas, R; Gelfand, JC; Gelfand, JM; Kim, EJ; Kirsch, IR; Leahy, DS; Rook, AH; Surber, C; Troxel, AB; Watanabe, R; Wysocka, M | 1 |
| Hengge, UR; Meykadeh, N | 1 |
| Bong, AB; Drewniok, C; Eberle, J; Geilen, CC; Gollnick, H; Schön, M; Schön, MP; Wienrich, BG | 1 |
| Liu, YH; Xu, KJ | 1 |
| Pillow, J; Skinner, RB; Woodmansee, C | 1 |
| Bichel, J; Lee, J; Meng, TC; Ortonne, JP; Stockfleth, E; Szeimies, RM | 1 |
1 review(s) available for resiquimod and Cancer of Skin
| Article | Year |
|---|---|
The role of topical immune response modifiers in skin cancer.
Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Cytokines; Humans; Imidazoles; Imiquimod; Models, Biological; Skin Neoplasms; Toll-Like Receptors | 2006 |
4 trial(s) available for resiquimod and Cancer of Skin
| Article | Year |
|---|---|
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
Topics: Administration, Topical; Aged; Cancer Vaccines; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Cytokines; Female; Gene Products, gag; HLA-A2 Antigen; Humans; Imidazoles; Male; MART-1 Antigen; Melanoma; Middle Aged; Peptide Fragments; Pilot Projects; Skin Neoplasms | 2019 |
Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma.
Topics: Administration, Topical; Adult; Aged; Antineoplastic Agents; Female; Humans; Imidazoles; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Skin; Skin Neoplasms; T-Lymphocytes | 2015 |
Death receptor-independent apoptosis in malignant melanoma induced by the small-molecule immune response modifier imiquimod.
Topics: Administration, Topical; Aminoquinolines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biopsy; Cell Line, Tumor; fas Receptor; Humans; Imidazoles; Imiquimod; Melanocytes; Melanoma; Membrane Glycoproteins; Proto-Oncogene Proteins c-bcl-2; Receptors, Tumor Necrosis Factor; Skin Neoplasms; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha | 2004 |
A phase II dose-ranging study of topical resiquimod to treat actinic keratosis.
Topics: Administration, Topical; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gels; Humans; Imidazoles; Keratosis; Male; Precancerous Conditions; Severity of Illness Index; Skin Neoplasms; Toll-Like Receptor 7; Treatment Outcome; Up-Regulation | 2008 |
4 other study(ies) available for resiquimod and Cancer of Skin
| Article | Year |
|---|---|
Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Topics: Animals; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Mice; Skin Neoplasms; Tumor Microenvironment | 2023 |
Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Animals; Antigens, Neoplasm; Cancer Vaccines; Cell Line, Tumor; Drug Carriers; Drug Compounding; Female; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Immunogenicity, Vaccine; Melanoma, Experimental; Membrane Proteins; Mice; Mice, Inbred C57BL; Nanoparticles; Oils; Peptide Fragments; Skin Neoplasms; Treatment Outcome | 2018 |
[Topical immunomodulators in dermatology].
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts | 2003 |
[Application of imiquimod and resiquimod in dermatology].
Topics: Adjuvants, Immunologic; Aminoquinolines; Antineoplastic Agents; Condylomata Acuminata; Humans; Imidazoles; Imiquimod; Skin Neoplasms | 2006 |